$855 Million is the total value of Rock Springs Capital Management LP's 93 reported holdings in Q4 2014. The portfolio turnover from Q3 2014 to Q4 2014 was 38.9% .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| MDT | Buy | MEDTRONIC INC | $39,710,000 | +21.5% | 550,000 | +4.3% | 4.64% | -8.1% |
| ABBV | Buy | ABBVIE INC | $37,955,000 | +25.2% | 580,000 | +10.5% | 4.44% | -5.4% |
| F113PS | New | COVIDIEN PLC | $30,173,000 | – | 295,000 | +100.0% | 3.53% | – |
| HCA | Buy | HCA HOLDINGS INC | $29,943,000 | +32.6% | 408,000 | +27.4% | 3.50% | +0.3% |
| MCK | Buy | MCKESSON CORP | $29,009,000 | +16.0% | 139,750 | +8.8% | 3.39% | -12.3% |
| AMGN | Buy | AMGEN INC | $25,646,000 | +25.9% | 161,000 | +11.0% | 3.00% | -4.8% |
| B108PS | Buy | ACTAVIS PLC | $22,652,000 | +7.0% | 88,000 | +0.3% | 2.65% | -19.1% |
| STJ | New | ST JUDE MED INC | $21,785,000 | – | 335,000 | +100.0% | 2.55% | – |
| CELG | Buy | CELGENE CORP | $21,589,000 | +37.2% | 193,000 | +16.3% | 2.52% | +3.7% |
| ACHC | Buy | ACADIA HEALTHCARE COMPANY IN | $20,184,000 | +105.0% | 329,750 | +62.4% | 2.36% | +55.0% |
| THOR | Buy | THORATEC CORP | $17,317,000 | +24.4% | 533,500 | +2.4% | 2.03% | -5.9% |
| ALXN | Buy | ALEXION PHARMACEUTICALS INC | $17,115,000 | +15.0% | 92,500 | +3.1% | 2.00% | -13.0% |
| TMH | Buy | TEAM HEALTH HOLDINGS INC | $15,332,000 | +75.4% | 266,500 | +76.8% | 1.79% | +32.6% |
| CVS | Buy | CVS HEALTH CORP | $14,447,000 | +39.6% | 150,000 | +15.4% | 1.69% | +5.6% |
| HUM | Buy | HUMANA INC | $13,824,000 | +33.5% | 96,250 | +21.1% | 1.62% | +0.9% |
| AET | Buy | AETNA INC NEW | $11,637,000 | +35.5% | 131,000 | +23.6% | 1.36% | +2.5% |
| EVHC | Buy | ENVISION HEALTHCARE HLDGS IN | $10,927,000 | +10.4% | 315,000 | +10.3% | 1.28% | -16.6% |
| PCYC | Buy | PHARMACYCLICS INC | $10,820,000 | +8.1% | 88,500 | +3.8% | 1.27% | -18.3% |
| HRC | Buy | HILL ROM HLDGS INC | $10,265,000 | +16.3% | 225,000 | +5.6% | 1.20% | -12.0% |
| OREX | Buy | OREXIGEN THERAPEUTICS INC | $10,211,000 | +91.8% | 1,685,000 | +34.8% | 1.19% | +44.9% |
| RTIX | Buy | RTI SURGICAL INC | $9,672,000 | +8.8% | 1,860,000 | +0.0% | 1.13% | -17.7% |
| XLV | New | SELECT SECTOR SPDR TRsbi healthcare | $9,573,000 | – | 140,000 | +100.0% | 1.12% | – |
| CI | Buy | CIGNA CORPORATION | $9,571,000 | +40.7% | 93,000 | +24.0% | 1.12% | +6.5% |
| TRNX | New | TORNIER N V | $9,499,000 | – | 372,500 | +100.0% | 1.11% | – |
| VRX | Buy | VALEANT PHARMACEUTICALS INTL | $9,052,000 | +23.2% | 63,250 | +12.9% | 1.06% | -6.9% |
| DHR | Buy | DANAHER CORP DEL | $9,042,000 | +40.0% | 105,500 | +24.1% | 1.06% | +5.9% |
| SLXP | New | SALIX PHARMACEUTICALS INC | $8,908,000 | – | 77,500 | +100.0% | 1.04% | – |
| HTWR | Buy | HEARTWARE INTL INC | $8,812,000 | +38.4% | 120,000 | +46.3% | 1.03% | +4.7% |
| CBST | Buy | CUBIST PHARMACEUTICALS INC | $8,807,000 | +185.5% | 87,500 | +88.2% | 1.03% | +115.9% |
| INCY | Buy | INCYTE CORP | $8,261,000 | +63.5% | 113,000 | +9.7% | 0.97% | +23.5% |
| NBIX | Buy | NEUROCRINE BIOSCIENCES INC | $8,042,000 | +62.9% | 360,000 | +14.3% | 0.94% | +23.2% |
| RCPT | Buy | RECEPTOS INC | $7,963,000 | +470.0% | 65,000 | +188.9% | 0.93% | +331.0% |
| JUNO | New | JUNO THERAPEUTICS INC | $7,542,000 | – | 144,426 | +100.0% | 0.88% | – |
| VRTX | Buy | VERTEX PHARMACEUTICALS INC | $7,484,000 | +15.9% | 63,000 | +9.6% | 0.88% | -12.4% |
| ABC | New | AMERISOURCEBERGEN CORP | $7,213,000 | – | 80,000 | +100.0% | 0.84% | – |
| PRGO | Buy | PERRIGO CO PLC | $7,104,000 | +66.0% | 42,500 | +49.1% | 0.83% | +25.5% |
| TSRO | Buy | TESARO INC | $6,973,000 | +45.9% | 187,500 | +5.6% | 0.82% | +10.4% |
| PRAH | New | PRA HEALTH SCIENCES INC | $6,903,000 | – | 285,000 | +100.0% | 0.81% | – |
| RAD | Buy | RITE AID CORP | $6,898,000 | +55.9% | 917,300 | +0.3% | 0.81% | +17.8% |
| MDCO | Buy | MEDICINES CO | $6,815,000 | +106.0% | 246,300 | +66.1% | 0.80% | +55.7% |
| KITE | Buy | KITE PHARMA INC | $6,602,000 | +180.8% | 114,474 | +38.8% | 0.77% | +112.1% |
| SRCL | Buy | STERICYCLE INC | $6,554,000 | +19.6% | 50,000 | +6.4% | 0.77% | -9.4% |
| NVDQ | Buy | NOVADAQ TECHNOLOGIES INC | $6,274,000 | +59.5% | 377,500 | +21.8% | 0.73% | +20.5% |
| RLYP | Buy | RELYPSA INC | $5,790,000 | +89.3% | 188,000 | +29.7% | 0.68% | +43.1% |
| STE | New | STERIS CORP | $5,253,000 | – | 81,000 | +100.0% | 0.61% | – |
| CNXR | New | CONNECTURE INC | $4,994,000 | – | 554,225 | +100.0% | 0.58% | – |
| ACHN | New | ACHILLION PHARMACEUTICALS IN | $4,471,000 | – | 365,000 | +100.0% | 0.52% | – |
| ZSPH | Buy | ZS PHARMA INC | $4,448,000 | +23.2% | 107,000 | +16.3% | 0.52% | -6.8% |
| TNDM | Buy | TANDEM DIABETES CARE INC | $4,445,000 | +19.6% | 350,000 | +26.4% | 0.52% | -9.6% |
| PBYI | Buy | PUMA BIOTECHNOLOGY INC | $4,401,000 | -10.0% | 23,250 | +13.4% | 0.52% | -32.0% |
| TBPH | Buy | THERAVANCE BIOPHARMA INC | $4,327,000 | +20.7% | 290,000 | +86.5% | 0.51% | -8.7% |
| FGEN | New | FIBROGEN INC | $4,137,000 | – | 151,300 | +100.0% | 0.48% | – |
| JAZZ | Buy | JAZZ PHARMACEUTICALS PLC | $4,093,000 | +39.7% | 25,000 | +37.0% | 0.48% | +5.7% |
| AERI | Buy | AERIE PHARMACEUTICALS INC | $4,087,000 | +98.9% | 140,000 | +41.0% | 0.48% | +50.3% |
| CHRS | New | COHERUS BIOSCIENCES INC | $3,918,000 | – | 240,051 | +100.0% | 0.46% | – |
| CYBX | Buy | CYBERONICS INC | $3,786,000 | +10.4% | 68,000 | +1.5% | 0.44% | -16.4% |
| NVAX | Buy | NOVAVAX INC | $3,766,000 | +57.0% | 635,000 | +10.4% | 0.44% | +18.9% |
| CO | Buy | CHINA CORD BLOOD CORP | $3,715,000 | -4.4% | 822,000 | +3.4% | 0.44% | -27.6% |
| REGN | New | REGENERON PHARMACEUTICALS | $3,692,000 | – | 9,000 | +100.0% | 0.43% | – |
| WX | Buy | WUXI PHARMATECH CAYMAN INC | $3,620,000 | +7.1% | 107,500 | +11.4% | 0.42% | -19.1% |
| EPZM | Buy | EPIZYME INC | $3,425,000 | -3.5% | 181,500 | +38.5% | 0.40% | -27.0% |
| CERU | Buy | CERULEAN PHARMA INC | $3,421,000 | +847.6% | 550,000 | +542.3% | 0.40% | +614.3% |
| FPRX | Buy | FIVE PRIME THERAPEUTICS INC | $3,240,000 | +140.2% | 120,000 | +4.3% | 0.38% | +81.3% |
| RARE | Buy | ULTRAGENYX PHARMACEUTICAL IN | $3,115,000 | -18.5% | 71,000 | +5.2% | 0.36% | -38.4% |
| CSLT | New | CASTLIGHT HEALTH INCcl b | $3,044,000 | – | 260,200 | +100.0% | 0.36% | – |
| ICPT | Buy | INTERCEPT PHARMACEUTICALS IN | $2,558,000 | -28.4% | 16,400 | +8.6% | 0.30% | -45.9% |
| TRIV | New | TRIVASCULAR TECHNOLOGIES INC | $2,489,000 | – | 198,000 | +100.0% | 0.29% | – |
| PFNX | Buy | PFENEX INC | $2,402,000 | +0.4% | 328,100 | +1.0% | 0.28% | -24.1% |
| BLUE | New | BLUEBIRD BIO INC | $2,293,000 | – | 25,000 | +100.0% | 0.27% | – |
| XNPT | Buy | XENOPORT INC | $2,061,000 | +162.5% | 235,000 | +61.0% | 0.24% | +99.2% |
| GWPH | New | GW PHARMACEUTICALS PLCads | $1,895,000 | – | 28,000 | +100.0% | 0.22% | – |
| ADXS | New | ADVAXIS INC | $1,802,000 | – | 225,000 | +100.0% | 0.21% | – |
| HRTX | Buy | HERON THERAPEUTICS INC | $1,610,000 | +176.2% | 160,000 | +128.6% | 0.19% | +108.9% |
| DERM | New | DERMIRA INC | $1,581,000 | – | 87,274 | +100.0% | 0.18% | – |
| BLCM | New | BELLICUM PHARMACEUTICALS INC | $806,000 | – | 35,000 | +100.0% | 0.09% | – |
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2015-02-17
Signatures
The EDGAR filing(s) were signed by:
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| INTUITIVE SURGICAL INC | 40 | Q3 2023 | 3.4% |
| NEUROCRINE BIOSCIENCES INC | 39 | Q3 2023 | 4.8% |
| PACIRA PHARMACEUTICALS INC | 39 | Q3 2023 | 2.6% |
| ULTRAGENYX PHARMACEUTICAL IN | 39 | Q3 2023 | 1.9% |
| ACADIA HEALTHCARE COMPANY IN | 38 | Q3 2023 | 4.4% |
| ASCENDIS PHARMA A/S | 35 | Q3 2023 | 1.3% |
| INVITAE CORP | 35 | Q3 2023 | 1.8% |
| BIOMARIN PHARMACEUTICAL INC | 35 | Q3 2023 | 1.3% |
| MACROGENICS INC | 35 | Q3 2023 | 0.5% |
| COLLEGIUM PHARMACEUTICAL INC | 34 | Q3 2023 | 2.1% |
View Rock Springs Capital Management LP's complete holdings history.
Latest significant ownerships (13-D/G)
| Filed | Shares | Percentage | |
|---|---|---|---|
| Aeglea BioTherapeutics, Inc. | February 14, 2023 | 3,413,906 | 5.6% |
| Compass Therapeutics, Inc. | February 14, 2023 | 5,333,188 | 4.2% |
| Mirum Pharmaceuticals, Inc. | February 14, 2023 | 1,795,733 | 4.9% |
| PhaseBio Pharmaceuticals IncSold out | February 14, 2023 | 0 | 0.0% |
| Sierra Oncology, Inc.Sold out | February 14, 2023 | 0 | 0.0% |
| ARDELYX, INC.Sold out | February 15, 2022 | 0 | 0.0% |
| CHIASMA, INCSold out | February 15, 2022 | 0 | 0.0% |
| FIVE PRIME THERAPEUTICS, INC.Sold out | February 15, 2022 | 0 | 0.0% |
| F-star Therapeutics, Inc. | February 15, 2022 | 751,889 | 3.6% |
| Protara Therapeutics, Inc.Sold out | February 15, 2022 | 0 | 0.0% |
View Rock Springs Capital Management LP's complete significant-ownership history.
Latest filings
| Type | Filed |
|---|---|
| 13F-HR | 2024-05-15 |
| SC 13G | 2024-05-01 |
| SC 13G/A | 2024-04-05 |
| 13F-HR | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
View Rock Springs Capital Management LP's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.